In 2005 Al was diagnosed with stage 4 COPD, with a 30% lung capacity and an approximate 4-year life expectancy. Lama Sing told Al that, in spite of the diagnosis of emphysema, this was not the case, and gave Al a regimen of suggestions. Al did remarkably well until 2017. As with most who have utmost faith, he applied all he knew to do to the best of his ability, yet while he defied all odds, he did not cure himself of this disease. It has been given many times by Lama Sing that dis-ease of any sort is always a choice. What is often not understood is that some choices are not infrequently made prior to incarnation for any variety of reasons. If and when those reasons have been fulfilled or even set aside, that one can choose to be released from the opportunity of the burden chosen.
It was not until several years into it that Al was tested and discovered to be “Alpha-1”. Remarkably, no pulmonologist ever suggested the treatment for Alpha-1, which is a replacement for the deficiency, and neither did Lama Sing volunteer it since that goes against Universal Law. Until May 2017, Al and Susan were unaware that a treatment for Alpha-1 even existed.
Given all this, the conclusion Al came to was that the purpose for this remained. He continued to live in peace and joy, dedicated to God and to the “Return.”
Al spent his final two years under the wonderful care of Hope Hospice.
Information on Alpha-1
What is Alpha-1?
Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic (inherited) condition – it is passed from parents to their children through their genes. Alpha-1 may result in serious lung disease in adults and/or liver disease at any age.
Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic condition passed from parents to their children through their genes. Because Alpha-1 is genetic, Alpha-1 lung disease is commonly called “genetic COPD.”
The specific treatment of Alpha-1-related lung disease is augmentation therapy, also called replacement therapy, the use of alpha-1 antitrypsin protein (AAT) from the blood plasma of healthy donors. The therapy is administered by a weekly intravenous infusion and, for now, is considered lifelong.
Augmentation therapy has been shown to reduce the rate of decline of lung function, and improve survival. It cannot restore lost lung function and is not considered a cure. However, this therapy is currently the standard of care for Alphas with COPD.